These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The GD2-specific 14G2a monoclonal antibody induces apoptosis and enhances cytotoxicity of chemotherapeutic drugs in IMR-32 human neuroblastoma cells. Kowalczyk A; Gil M; Horwacik I; Odrowaz Z; Kozbor D; Rokita H Cancer Lett; 2009 Aug; 281(2):171-82. PubMed ID: 19339105 [TBL] [Abstract][Full Text] [Related]
5. Immunotherapy with GD2 specific monoclonal antibodies. Cheung NK; Medof ME; Munn D Prog Clin Biol Res; 1988; 271():619-32. PubMed ID: 3043454 [No Abstract] [Full Text] [Related]
6. [Gangliosides as carbohydrate antigens associated with cancer and their possible use in tumor immunotherapy]. Horwacik I Przegl Lek; 2004; 61 Suppl 2():14-9. PubMed ID: 15686040 [TBL] [Abstract][Full Text] [Related]
7. Antibody-based immunotherapy in high-risk neuroblastoma. Johnson E; Dean SM; Sondel PM Expert Rev Mol Med; 2007 Dec; 9(34):1-21. PubMed ID: 18081947 [TBL] [Abstract][Full Text] [Related]
8. [Immunotherapy of poor-prognosis neuroblastoma in children: from bench to bedside]. Rousseau R; Combaret V; Yvon E; Schell M; Philip I; Puisieux A; Frappaz D; Philip T; Bergeron C Bull Cancer; 2006 Feb; 93(2):153-61. PubMed ID: 16517413 [TBL] [Abstract][Full Text] [Related]
9. [Nursing care for a child with recurrent neuroblastoma treated with immunotherapy]. Mast C Kinderkrankenschwester; 2012 Apr; 31(4):142-4. PubMed ID: 22594170 [No Abstract] [Full Text] [Related]
10. State of the art in immunotherapy of neuroblastoma. Jabbari P; Hanaei S; Rezaei N Immunotherapy; 2019 Jun; 11(9):831-850. PubMed ID: 31094257 [TBL] [Abstract][Full Text] [Related]
11. Iodine 131 labeled GD2 monoclonal antibody in the diagnosis and therapy of human neuroblastoma. Cheung NK; Miraldi FD Prog Clin Biol Res; 1988; 271():595-604. PubMed ID: 3406022 [No Abstract] [Full Text] [Related]
13. Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapy. Perez Horta Z; Goldberg JL; Sondel PM Immunotherapy; 2016 Sep; 8(9):1097-117. PubMed ID: 27485082 [TBL] [Abstract][Full Text] [Related]
14. Potential of genetically engineered monoclonal antibodies for cancer immunotherapy. Reisfeld RA Pigment Cell Res; 1992; Suppl 2():109-12. PubMed ID: 1409412 [No Abstract] [Full Text] [Related]
15. Dinutuximab for maintenance therapy in pediatric neuroblastoma. McGinty L; Kolesar J Am J Health Syst Pharm; 2017 Apr; 74(8):563-567. PubMed ID: 28389455 [TBL] [Abstract][Full Text] [Related]
16. Immune therapies for neuroblastoma. Navid F; Armstrong M; Barfield RC Cancer Biol Ther; 2009 May; 8(10):874-82. PubMed ID: 19342881 [TBL] [Abstract][Full Text] [Related]
17. Immunotherapy improves survival for patients with neuroblastoma. McBride D ONS Connect; 2009 Aug; 24(8):17. PubMed ID: 19715061 [No Abstract] [Full Text] [Related]
18. Therapeutic application of radiolabelled monoclonal antibody UJ13A in children with disseminated neuroblastoma--a phase 1 study. Kemshead JT; Goldman A; Jones D; Pritchard J; Malpas JS; Gordon I; Malone JF; Hurley GD; Breatnach F Prog Clin Biol Res; 1985; 175():533-44. PubMed ID: 4039447 [No Abstract] [Full Text] [Related]
19. Immunotherapy for neuroblastoma: turning promise into reality. Gray JC; Kohler JA Pediatr Blood Cancer; 2009 Dec; 53(6):931-40. PubMed ID: 19591222 [TBL] [Abstract][Full Text] [Related]
20. [Immunotherapy--nursing requirements--presentation of care in immunotherapy with monoclonal antibodies as a part of the treatment of metastasized neuroblastoma IV]. Lehner C Kinderkrankenschwester; 1998 Nov; 17(11):476-80. PubMed ID: 9887744 [No Abstract] [Full Text] [Related] [Next] [New Search]